<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500860</url>
  </required_header>
  <id_info>
    <org_study_id>Cairo University</org_study_id>
    <nct_id>NCT04500860</nct_id>
  </id_info>
  <brief_title>Low Dose Tadalafil for Treatment of Female OAB Syndrome: Short Term Follow up.</brief_title>
  <official_title>Low Dose Tadalafil 5mg for Treatment of Female Overactive Bladder Syndrome :6 Months Follow up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of use of low dose tadalafil 5 mg daily for treatment of female OAB syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      100 female patients with overactive bladder syndrome divided into 2 groups group A subjected&#xD;
      to daily low dose tadalafil 5 mg and group B subjected to placebo . Both are evaluated as&#xD;
      using OAB symptoms score for 6 months follow up&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of daily low dose tadalafil 5mg in treatment of female overactive bladder syndrome: 6 months follow up</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluation of efficacy of tadalafil 5 mg</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Female Patients With Overactive Bladder Syndrome or Female Patients With Urgency or Urgency Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>Group A Tadalafil 5 mg</arm_group_label>
    <description>50 patients subjected to Daily dose of tadalafil 5mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B placebo</arm_group_label>
    <description>50 patients subjected to placebo daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose tadalafil 5 mg</intervention_name>
    <description>Efficacy of daily low dose tadalafil 5mg for treatment of female overactive bladder syndrome or urgency with or without urgency urinary incontinence</description>
    <arm_group_label>Group A Tadalafil 5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Females , any age, no neurologic abnormality, with OAB syndrome, urgency or urgency urinary&#xD;
        incontinence&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any female with overactive bladder syndrome, urgency with or without urgency urinary&#xD;
             incontinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active Urinary tract infection&#xD;
&#xD;
          -  neurologic abnormality&#xD;
&#xD;
          -  Pure Stress urinary incontinence&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 3, 2020</last_update_submitted>
  <last_update_submitted_qc>August 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Samer Morsy</investigator_full_name>
    <investigator_title>Urology lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

